{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Yamakawa K"],"pubmed_abstract":["The coronavirus disease (COVID-19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J-SSCG) 2020 Special Committee created the Japanese rapid/living recommendations on drug management for COVID-19 using the experience of creating the J-SSCGs. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on 9 September, 2020, and this document is the revised edition (version 3.1) (released 30 March, 2021). Clinical questions (CQs) were set for the following seven drugs: favipiravir (CQ1), remdesivir (CQ2), hyd"],"journal":["Acute medicine & surgery"],"pagination":["e664"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8209876"],"repository":["biostudies-literature"],"pubmed_title":["Japanese rapid/living recommendations on drug management for COVID-19."],"pmcid":["PMC8209876"],"pubmed_authors":["Kawasaki T","Ogura H","Okano H","Aihara M","Tanaka H","Narita C","Imura H","Hara Y","Egi M","Yamada H","Ishimaru G","Shime N","Yamamoto R","Yasuda H","Terayama T","Yamada K","Yamakawa K","Mayumi T","Nishida O","Hasegawa D","Doi K","Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J‐SSCG 2020), the COVID‐19 Task Force","Ishihara T","Hashimoto H"],"additional_accession":[]},"is_claimable":false,"name":"Japanese rapid/living recommendations on drug management for COVID-19.","description":"The coronavirus disease (COVID-19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J-SSCG) 2020 Special Committee created the Japanese rapid/living recommendations on drug management for COVID-19 using the experience of creating the J-SSCGs. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on 9 September, 2020, and this document is the revised edition (version 3.1) (released 30 March, 2021). Clinical questions (CQs) were set for the following seven drugs: favipiravir (CQ1), remdesivir (CQ2), hyd","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan-Dec","modification":"2025-04-04T20:57:35.349Z","creation":"2022-02-10T19:38:53.318Z"},"accession":"S-EPMC8209876","cross_references":{"pubmed":["34178358"],"doi":["10.1002/ams2.664"]}}